Matrix Metalloproteinase 3 Gene Polymorphism and Its Level Predict Morbidity After Acute Myocardial Infarction
- 28 December 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 145 (1) , 134-139
Abstract
Matrix metalloproteinase is responsible for ventricular remodeling after acute myocardial infarction (MI). The purpose of the present study was to determine whether the matrix metalloproteinase 3 (MMP-3) polymorphism and its level predict morbidity after acute MI (AMI). We studied 112 patients with AMI and 140 controls. All patients were followed for AMI complications during their hospitalization and 6 months after. Serum MMP-3 was measured. MMP-3-1612 5A/6A polymorphism was genotyped by polymerase chain reaction. We observed that the serum MMP-3 levels were significantly increased in patients with AMI with morbidity compared with patients without complications. Also, MMP-3 levels in patients with AMI carrying 5A/5A were elevated compared with those carrying 6A/6A. The frequencies of 5A/5A genotypes were significantly increased in patients with AMI compared with controls, and patients with AMI carrying 5A/5A had a fivefold increased risk of developing morbidity. The impairment of left ventricular function (ΔFS [fractional shortening] and ΔEF [ejection fraction]) was observed more in the 5A/5A genotype compared with the 6A/6A genotype. A significant inverse correlation between predischarge MMP-3 levels and FS and EF was found at 6 months follow-up. MMP-3 polymorphism has a significant association with the risk of developing morbidity after AMI. Higher predischarge MMP-3 levels are associated with left ventricular dysfunction after AMI.Keywords
This publication has 28 references indexed in Scilit:
- Association between the polymorphisms of matrix metalloproteinases 9 and 3 genes and risk of myocardial infarction in Egyptian patientsEgyptian Journal of Medical Human Genetics, 2013
- Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarctionCoronary Artery Disease, 2010
- Matrix metalloproteinase-3 (MMP-3) -1612 5A/6A promoter polymorphism in coronary artery disease in Indian populationIndian Journal of Clinical Biochemistry, 2010
- Circulating Stromelysin-1 (MMP-3): A Novel Predictor of LV Dysfunction, Remodelling and All-Cause Mortality After Acute Myocardial InfarctionEuropean Journal of Heart Failure, 2008
- Matrix metalloproteinase-3 and coronary remodelling: Implications for unstable coronary diseaseCardiovascular Research, 2007
- Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort studyEuropean Heart Journal, 2007
- Matrix metalloproteinase gene polymorphisms in patients with coronary artery diseaseGenetics and Molecular Biology, 2007
- Comparison of Levels of Matrix Metalloproteinase-2 and -3 in Patients With Ischemic Cardiomyopathy Versus Nonischemic CardiomyopathyThe American Journal of Cardiology, 2005
- Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunctionEuropean Heart Journal, 2004
- Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han populationThrombosis and Haemostasis, 2004